Business Context and Reporting Period
This Form 6-K filing by Immuron Limited covers the month of November 2018. The registrant is a foreign private issuer based in Carlton South, Victoria, Australia, and files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to disclose a corporate governance announcement and does not contain financial statements or performance data.
Material Changes
The primary material change disclosed is the appointment of Gary S. Jacob, Ph.D., as the new Chief Executive Officer. Dr. Jacob is described as an experienced US-based biotechnology executive.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, management commentary on operations, or discussion of risks and contingencies. The document explicitly states it is not deemed "filed" for purposes of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other filings except as expressly set forth.
Key Facts for Investor Verification
- Immuron Limited appointed Gary S. Jacob, Ph.D., as Chief Executive Officer on November 19, 2018.
- The appointment was originally announced to the Australian Securities Exchange (ASX).
- This Form 6-K does not include financial results or operational metrics for the period.